Combining Therapies in Inflammatory Bowel Disease: End of the Line or a New Era?

Ciaran Judge; Reza Saeidi; Kathleen Sugrue; Louise Rabbitt; Aine Keogh; Clodagh Byron; Syed Akbar Zulquernain; Sarah Gleeson; Aoibhlinn O'Toole; Martin Buckley; Eoin Slattery; Glen Doherty; Jane McCarthy

doi:10.1093/ibd/izab028

Combining Therapies in Inflammatory Bowel Disease: End of the Line or a New Era?

Inflamm Bowel Dis. 2021 May 17;27(6):956-959. doi: 10.1093/ibd/izab028.

Authors

Ciaran Judge^{1

2}, Reza Saeidi^{1

3}, Kathleen Sugrue^{1

2}, Louise Rabbitt^{1

4}, Aine Keogh^{1

4}, Clodagh Byron^{1

5}, Syed Akbar Zulquernain^{1

5}, Sarah Gleeson^{1

2}, Aoibhlinn O'Toole^{1

6}, Martin Buckley^{1

2}, Eoin Slattery^{1

4}, Glen Doherty^{1

3}, Jane McCarthy^{1

2}

Affiliations

¹ INITIative, Investigator Network for Inflammatory Bowel Disease Therapy in Ireland, Dublin, Ireland.
² Department of Gastroenterology, Mercy University Hospital, Cork, Ireland.
³ Department of Gastroenterology and Colorectal Disease, St Vincent's University Hospital, Dublin, Ireland.
⁴ Department of Gastroenterology, Galway University Hospital, Galway, Ireland.
⁵ Department of Gastroenterology, Cork University Hospital, Cork, Ireland.
⁶ Department of Gastroenterology, Beaumont University Hospital, Dublin, Ireland.

PMID: 33544119
DOI: 10.1093/ibd/izab028

No abstract available

Keywords: Crohn’s disease; IBD; biologics; combined biologics; combined targeted treatment; small molecules; ulcerative colitis.

MeSH terms

Humans
Inflammatory Bowel Diseases* / drug therapy